Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: biajj / Re: Very disappointing correction to what was a gratitutiously offered

I was pretty happy that RG was willing to issue guidance back when he did, and I thought FINALLY, at least he's trying to get the company to behave outwardly like NORMAL companies to, (at least on the one small part of the company that he presumbably controls).

That being said, when you put it into the context that PTSC hasn't issued guidance before on ANYTHING revenue wise that I can recall (at least not in the last 4 years), and you realize that this is the first time, it adds extra significance to the guidance, IMO, and it's doubly disappointing that they have to retract it, though I'm glad they communicated it.

As for transparency about the MMP, IMO, the '584 treatment will give a hint as to if we'll ever get any. And while I echo your cal for compensation reductions based on this and previous failed performance, I'd much prefer a compensation ELIMINATION along with the actual compensatee for certain positions.

When you think about the FACT that if PTSC had simply taken its share of the $100M or so it earned in MMP revs, paid the taxes on it, and put the other $65M in the bank to earn interest, even if they only got a 3% return, they could be making nearly $2M a year. Fire everyone except a CEO/CFO to do the books, pay them $150K, and we'd be pulling in profits of $1.8M per year.

Instead, .....well, enough said.

Share
New Message
Please login to post a reply